Side-by-side · Research reference
BPC-157vsGHK-Cu
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED7/53 cited
BHuman-MechanisticHUMAN-REVIEWED4/47 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
BPC-157
GHK-Cu
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillin
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Replaces declining endogenous levels
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
GHK-Cu
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
—
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
Daily or 2–3× per week (SQ)
Lower / starter dose
200 mcg / day
Conservative starter for new users.
0.5 mg / day SQ
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Human-mechanistic + topical clinical studies
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
8–12 weeks for visible skin / hair effect
Reconstitution
Bacteriostatic water, 1–2 mL
Bacteriostatic water; light-protected
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
No specific time; evening preferred for topicals
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
Hours (estimated; rapid tissue uptake)
Standard SQ dose
—
1–2 mg / day
Anecdotal injectable range; topical creams use 0.1–2% solutions.
Topical concentration
—
0.1–2.0% in serum / cream
04Side Effects & Safety
Parameter
BPC-157
GHK-Cu
Injection site reaction
Mild irritation (anecdotal)
Erythema, mild pruritus (common)
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid topical and SQ — insufficient data
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Topical irritation
—
Mild redness, transient stinging
Copper accumulation
—
Theoretical with very high chronic doses
Allergic reaction
—
Rare hypersensitivity to copper
Wilson disease
—
Contraindicated
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
05Administration Protocol
Parameter
BPC-157
GHK-Cu
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Anytime; evening preferred. Topical: apply to clean dry skin.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair